IN8BIO

IN8bio was founded with the mission of developing next-generation cellular therapies for treating cancer. Dr. Lawrence Lamb, one the Company's co-founders, is a leader in the field of gamma-delta T cells. During his postdoctoral fellowship in transplant medicine, he was the first to describe homeostatic reconstitution of gamma-delta T cells in patients who receive alpha-beta T cell depleted bone marrow grafts. Dr. Lamb also identified an association between gamma-delta T cell levels and disease-free survival in allogeneic bone marrow transplantation. This work formed the foundation of IN8bio's focus on delivering gamma-delta therapeutics for the treatment of cancer. The Company is developing allogeneic, autologous, iPSC and genetically modified gamma-delta T cell therapies. Dr. Lamb's research has formed the basis for the company's Phase 1 and Phase 2 clinical trials, two in newly-diagnosed Glioblastoma and one in leukemia and lymphoma patients undergoing hematopoietic bone marrow..

Also known as: In8bio, Inc.

Primary location: Birmingham United States